Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.

Abstract Aims The aim of the current study is to investigate the effect of fenofibrate alone and in combination with pioglitazone on serum sirtuin 1 and fetuin A of obese patients with Type 2 Diabetes Mellitus (T2DM). Methods Intervention effect on inflammatory parameters was assessed before and after treatment. The study was conducted on 60 postmenopausal females of whom, only 44 patients completed the study. They were distributed as follows; obese patients without T2DM ( n  = 15) who administered fenofibrate (160 mg/day) once for 8 weeks, obese patients with T2DM ( n  = 15) who administered fenofibrate (160 mg/day) once for 8 weeks, obese patients with T2DM ( n  = 14) who administered fenofibrate (160 mg/day) and pioglitazone (15 mg/day) combination once for 8 weeks. We measured fasting plasma glucose, glycated hemoglobin (HbA 1c ), serum lipids. Inflammatory markers (high sensitivity C-reactive protein “hs-CRP”, interleukin-6 “IL-6”, fetuin A, and sirtuin 1) of patients were measured in serum using enzyme-linked immunoassay (ELISA) kits. Results Sirtuin 1 levels in obese patients with T2DM were significantly lower than its levels in obese patients while fetuin A levels were significantly higher ( P P Conclusions Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients. Trial number PACTR201407000856135